A biotech start-up teamed up with technology giants like Apple to continuously monitor people with Parkinson’s disease so that they could personalize their treatments in the clinic and the lab.
Researchers are developing gene and cell therapies and prosthetics to help patients with blindness regain some vision. The first major prosthetic, the Argus II, was just discontinued. Where will the field go from here?
Researchers no longer think that proteins blindly swim through the cytoplasm hoping to bump into one another. Instead, they intentionally aggregate with other biomolecules, forming membrane free, transient organelles called condensates.
The company plans to develop more specialized, antibody-based GPCR drugs to treat a myriad of diseases. They recruited a leader in overseeing successful clinical trials to get the job done.
We’ve updated our Privacy Policy to make it clearer how we use your personal data. Please read our Cookie Policy to learn how we use cookies to provide you with a better experience.